Shares of Pulse Biosciences, Inc (NASDAQ:PLSE – Get Free Report) reached a new 52-week high during mid-day trading on Monday after Canaccord Genuity Group raised their price target on the stock from $58.00 to $74.00. Canaccord Genuity Group currently has a buy rating on the stock. Pulse Biosciences traded as high as $58.94 and last traded at $56.8660, with a volume of 65,842 shares changing hands. The stock had previously closed at $53.29.
Several other brokerages also recently commented on PLSE. Mizuho set a $65.00 target price on Pulse Biosciences in a research note on Friday. Wall Street Zen raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, September 6th. BTIG Research started coverage on Pulse Biosciences in a research note on Wednesday, September 23rd. They issued a “buy” rating and a $70.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a report on Thursday, October 15th. Finally, Freedom Capital raised shares of Pulse Biosciences to a “strong-buy” rating in a report on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $66.60.
Check Out Our Latest Stock Analysis on Pulse Biosciences
Insider Buying and Selling
In related news, COO Liane Teplitsky acquired 1,036 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The stock was bought at an average price of $48.23 per share, for a total transaction of $49,966.28. Following the acquisition, the chief operating officer directly owned 1,036 shares of the company’s stock, valued at $49,966.28. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last quarter, insiders have bought 4,095 shares of company stock valued at $199,931. Company insiders own 74.00% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Osterweis Capital Management Inc. purchased a new position in shares of Pulse Biosciences in the second quarter worth $28,000. Sterling Capital Management LLC grew its holdings in Pulse Biosciences by 844.6% during the third quarter. Sterling Capital Management LLC now owns 614 shares of the company’s stock worth $31,000 after acquiring an additional 549 shares during the period. Jupiter Topco LLC acquired a new stake in shares of Pulse Biosciences during the 2nd quarter worth approximately $241,000. Axxcess Wealth Management LLC purchased a new position in Pulse Biosciences in the third quarter valued at $242,000. Finally, GSA Capital Partners LLP purchased a new position in shares of Pulse Biosciences in the 2nd quarter valued at about $290,000. 76.95% of the stock is currently owned by hedge funds and other institutional investors.
Pulse Biosciences Price Performance
The firm has a fifty day simple moving average of $51.55 and a 200 day simple moving average of $32.28. The company has a market capitalization of $4.15 billion, a price-to-earnings ratio of -47.17 and a beta of 1.65.
Pulse Biosciences (NASDAQ:PLSE – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.01). The business had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.52 million. Pulse Biosciences had a negative net margin of 5,603.88% and a negative return on equity of 101.91%. The firm’s quarterly revenue was down 54.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.29) earnings per share. Research analysts predict that Pulse Biosciences, Inc will post -1.34 EPS for the current year.
Pulse Biosciences Company Profile
Featured Stories
- Five stocks we like better than Pulse Biosciences
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
